Allergy & Immunology
Food protein-induced enterocolitis syndrome: A large French multicentric experience.
25 Mar, 2022 | 08:27h | UTC
RCT: Inhibition of Prekallikrein for hereditary angioedema.
23 Mar, 2022 | 10:02h | UTCInhibition of Prekallikrein for Hereditary Angioedema – New England Journal of Medicine (link to abstract – $ for full-text)
Related:
Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.
Evaluation and Management of Angioedema in the Emergency Department
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity.
21 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severityhttps://t.co/iFL1AD4q2l@pvmarkov, @ArisKatzourakis & Stilianakis argue that ongoing rapid antigenic evolution is likely to produce new variants that may escape immunity and be more severe. pic.twitter.com/BddNu5DZaq
— Nature Reviews Microbiology (@NatureRevMicro) March 14, 2022
Systematic Review: Strategies for using topical corticosteroids in children and adults with eczema.
21 Mar, 2022 | 08:33h | UTCStrategies for using topical corticosteroids in children and adults with eczema – Cochrane Library
Summary: What is the best way to use topical corticosteroids to treat people with eczema? – Cochrane Library
Commentary on Twitter
What is the best way to use topical #corticosteroids to treat people with #eczema?
"Generally, stronger topical corticosteroids are probably more effective than weaker preparations". https://t.co/iaH6fzyXL4Read the latest evidence from @CochraneSkin @CebdNottm pic.twitter.com/f01BO2FyDs
— Cochrane UK (@CochraneUK) March 17, 2022
Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.
18 Mar, 2022 | 08:09h | UTCProphylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly
Follow-up data from 2 randomized trials: efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis.
18 Mar, 2022 | 07:48h | UTC
Another study suggests that a third vaccine dose is necessary to protect populations against the omicron variant.
11 Mar, 2022 | 10:14h | UTCNews Release: Third vaccine dose critical for protecting populations against omicron variant – BMJ Newsroom
Commentary on Twitter
mRNA vaccines are highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants. But three doses are needed to achieve a similar level of protection against omicron, finds a large US study: https://t.co/YMm176gmby
— The BMJ (@bmj_latest) March 10, 2022
RCT: Reliever-triggered inhaled glucocorticoid reduces severe exacerbations in black and latinx adults with moderate-to-severe asthma.
9 Mar, 2022 | 10:06h | UTCReliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma – New England Journal of Medicine (link to abstract – $ for full-text)
How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain.
8 Mar, 2022 | 08:56h | UTC
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
[Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.
1 Mar, 2022 | 08:54h | UTCCommentaries:
Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT
More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP
Guideline: Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis.
27 Feb, 2022 | 22:40h | UTC
Commentary on Twitter
New rapid recommendation makes a weak recommendation against plasma exchange in patients with low risk of end stage kidney disease, and a weak recommendation in favour of plasma exchange in patients with moderate-high risk of ESKD https://t.co/PeEjSuRIxI #BMJInfographic pic.twitter.com/YR55t6XYhS
— The BMJ (@bmj_latest) February 25, 2022
RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.
24 Feb, 2022 | 10:20h | UTCCommentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
24 Feb, 2022 | 10:30h | UTCFourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature
Original Study: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv
Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.
24 Feb, 2022 | 10:23h | UTCCommentaries:
Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD
Review: Pruritus in pregnancy.
23 Feb, 2022 | 09:59h | UTCPruritus in Pregnancy – American Journal of Clinical Dermatology
Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches.
23 Feb, 2022 | 10:01h | UTC
Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.
22 Feb, 2022 | 10:05h | UTC
Commentary on Twitter
Systematic review and meta-analysis of 22 studies and 1366 patients found that there was a low risk of repeat allergic reaction to a second #COVID19 mRNA vaccine dose in people who had immediate allergic reaction with the first dose. https://t.co/NQSXBJwa6r
— JAMA Internal Medicine (@JAMAInternalMed) February 21, 2022
Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.
22 Feb, 2022 | 10:07h | UTCWhy one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian
Commentary from the author on Twitter (thread – click for more)
My new essay @guardian
"Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed"https://t.co/RaBUpET2CZ
Summarizes extensive new evidence that confirmed Prior Covid ("Natural Immunity" or NI) + 1-shot is as protective as 3-shots /1— Eric Topol (@EricTopol) February 20, 2022
AAAAI Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia.
21 Feb, 2022 | 08:45h | UTC
Overview of Allergy and Anaphylaxis.
21 Feb, 2022 | 08:28h | UTCOverview of Allergy and Anaphylaxis – Emergency Clinics of North America
New U.S. childhood and adolescent immunization schedule released by ACIP.
18 Feb, 2022 | 10:05h | UTCRecommended Childhood and Adolescent Immunization Schedule: United States, 2022 – Pediatrics
See also:
New U.S. adult immunization schedule released by ACIP.
18 Feb, 2022 | 10:07h | UTCRecommended Adult Immunization Schedule, United States, 2022 – Annals of Internal Medicine
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
EAACI Position Paper: Hypersensitivity reactions to chemotherapy.
15 Feb, 2022 | 09:54h | UTCHypersensitivity reactions to chemotherapy: an EAACI Position Paper – Allergy